Fig. 3.

Additive effect of a PI3-K inhibitor on the anti-tumor activity of doxorubicin in Caki-2 cells. Caki-2 cells were treated with LY294002 at the indicated concentrations in the absence (open columns) or presence (filled columns) of 1 μM doxorubicin for 24 h. (A) Morphologies of RCCs treated with 30 μM LY294002 and/or 1 μM doxorubicin were photographed by phase contrast. 30 μM LY294002 1 μM doxorubicin Scale bar=50 µm. (B) Cell viabilities were determined by MTT reducing activity. Data are expressed as means±SE. (n=6). ^**P<0.01, compared with control. ##P<0.01, compared with LY294002 alone.